4 July 2026 in Biological Products. Prevention, Diagnosis, Treatment
INTRODUCTION . The development of a biopharmaceutical drug for enzyme replacement therapy based on recombinant acid α-1,4-glucosidase (α-glucosidase) is a pressing task, the solution of which could provide patients with Pompe disease in the Russian Federation with the necessary amount of the drug. This study demonstrates an effective method for developing, from the CHO-K1 cell line, a stable industrial producer clone that produces active α-glucosidase. AIM . This study aimed to develop monoclonal cell lines producing recombinant acid α-glucosidase and to evaluate the stability of growth characteristics and productivity during cultivation over 60 generations. MATERIALS AND METHODS . The suspension CHO-K1 cell line (ECACC) was cultured in BalanCD Growth A medium. Cell transfection was performed by electroporation using the MaxCyte system (according to the CHO protocol). Selection of producers was carried out using puromycin (5 μg/mL). Cloning was performed using a cell dispensing system based on microfluidic technology (C.SIGHT). The monoclonality of the cell lines was confirmed using an automated cell imaging system (Cell Metric CLD). The concentration of α-glucosidase in the culture fluid was determined by enzyme-linked immunosorbent assay. Enzyme activity was measured by a colorimetric method using the substrate 4-nitrophenyl-α-D-glucopyranoside (pNP-α-D-Glc). RESULTS . Screening of 1000 producers was performed, resulting in the selection of 22 cell lines with a productivity of 0.14–0.65 g/L. The lead α-glucosidase producer GAA-14 was cloned, followed by confirmation of monoclonality. A panel of 20 monoclonal lines was obtained. The specific activity of the enzyme and the mannose-6-phosphate residue (М6Р) content did not differ from those of the reference drug (4.3±0.9 U/mg and 0.99±0.10 mol M6P/mol protein, respectively). When studying the stability of the lead clone over 60 generations, preservation of growth characteristics (viability, 98.5±1.5%; population doubling time, 20.0±1.3 h; and productivity, 450±20 mg/L) was demonstrated under batch cultivation over 7 days. CONCLUSIONS. A stable monoclonal α-glucosidase producer cell line based on CHO-K1 cells has been developed, yielding the active enzyme at 0.45 g/L on day 7. The resulting producer clone is suitable for scale-up and manufacture of the drug substance for preclinical studies.
4 July 2026 in Biological Products. Prevention, Diagnosis, Treatment
INTRODUCTION. Artificial promoters based on the chicken beta-actin promoter (CAG, CBA, or CB) are frequently used in recombinant adeno-associated virus (rAAV)-based gene therapy products. However, data on the activity and age-related activity dynamic of these promoters remain quite limited. In this study, we quantitatively assessed CAG promoter activity in various organs of postnatal mice to determine its suitability for the development of rAAV-mediated gene therapy. AIM . Evaluation of the relative CAG promoter activity and its dynamics in mouse organs from 3 to 12 weeks of life. MATERIALS AND METHODS . Two-day-old ICR (CD-1) mice were injected once with rAAV9 carrying a cassette for SMN expression under the control of the CAG promoter. At 3, 6, and 12 weeks after administration, total DNA and RNA were isolated from organ samples (brain, spinal cord, liver, lungs, heart, quadriceps femoris muscle). The content of rAAV genomes and SMN mRNA in nucleic acid preparations were determined by quantitative PCR. Relative promoter activity was calculated as the ratio of the SMN mRNA concentration to the concentration of rAAV genomes, normalized on the RNA:DNA ratio in the organ. Data were analyzed using the geometric mean and regression analysis. RESULTS. CAG promoter activity varies significantly in different organs. At week 3 after injection, the highest values were observed for the quadriceps femoris muscle, 4.7–9.7 times higher than those in other organs. It was also found that in the brain and lungs, promoter activity decreased 4.7-fold (p=0.0094) and 5.2-fold (p=0.0039), respectively, from 3 to 12 weeks after injection, while in other tissues no significant changes in activity were observed. CONCLUSIONS . The CAG promoter is poorly suited for transgene expression in the lung and brain cells due to promoter silencing and is suboptimal for expression in the liver cells because of relatively low activity; these findings should be taken into account in the development of gene therapy products.